Cytovale®, a commercial-stage medical diagnostics company, today announced the appointment of Rhonda Collins, DNP, RN, FAAN, as the company's first chief nursing officer (CNO). A former nurse, ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

The global blood banking equipment market is on track for significant expansion, with sales expected to climb from USD 16,322.1 million in 2024 to USD 25,591.4 million by 2034, reflecting a 4.6% ...

Fresenius Kabi's plant on Grand Island has a slogan: Saving lives one vial at a time. The plant, which employs about 800 people, makes sterile, injectable pharmaceuticals, used in doctors' offices ...

The company's restructuring into two segments, Helios and Kabi, has driven growth, particularly in the high-potential biosimilar market. Fresenius has reduced its debt levels and reinstated its ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

Gdansk: German healthcare group Fresenius reported fourth-quarter adjusted operating profit above market estimates on Wednesday, citing strong performance at its Kabi and Helios divisions.

The joint company will be 55% owned by Vifor Pharma and 45% by Fresenius Kabi. Fresenius Kabi will be fully responsible for the marketing of Vifor’s intravenous iron portfolio in China.

Aurora™ is the automated system that streamlines plasma collection, producing virtually cell-free plasma and providing an improved experience for both operators and donors. The system separates ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) scored a major legal win on December 3, 2024, when the U.S. District Court ruled in the company’s favor in a patent dispute with Fresenius Kabi USA ...